

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED #5  
OCT 10 2003 10/14/03  
TECH CENTER 10002000  
RECEIVED  
OCT 09 2003  
TC 1700

In re application of:  
Yusuf K. HAMIED et al.

Appl. No: 10/026,949 ✓

Confirmation No: 7990

Filed: December 27, 2001 ✓

For: PHARMACEUTICAL COMPOSITION  
CONTAINING NEW POLYMORPHIC  
FORMS OF OLANZAPINE AND USES  
THEREOF ✓

Art Unit: 1624

Examiner: *Unassigned*

Atty. Docket No: 33396-177202

Customer No:

**26694**

PATENT TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Post Office Box 1450  
Alexandria, Virginia 22313-1450

Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b).

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO-1449 and which the Examiner may deem relevant to patentability of the claims of the above-identified application. Also enclosed is a PCT search report prepared by the European Patent Office in related PCT application No. PCT/GB00/04982 (published as WO/0147933). The relevance of each document is shown on the search report.

U.S. Patent No. 5,919,485 is already of record. Copies of EP 0 831 097 A, WO 0018408 and newly cited U.S. Patent No. 6,251,895 are attached. According to the search report, EP 0 733 635 corresponds to US Patent No. 5,736,541, which is already of record. If the Examiner would like a copy of the European patent, please contact undersigned counsel. It is believed that the Examiner can obtain a copy of the Houben-Weyl reference under a reciprocity agreement


with the European Patent Office, as the PCT application designates the US. However, if a copy of the document is desired, please inform undersigned counsel and a copy of the missing document will be supplied.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In view of the above, no further translation or statement of relevance is required, and as all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information Disclosure Statements have been complied with, and it is therefore respectfully requested that the Examiner consider the documents and make them of record.

Please charge any necessary fee or credit any overpayment in connection with this Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfully submitted,



Keith G. Haddaway, Ph.D.

Registration No. 46,180

VENABLE

P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000

Telefax: (202) 344-8300

Date: October 8, 2003

DC2#489792